Christopher Baethge

Christopher Baethge

Auto-generated profile, based on publicly available information

Christopher Baethge

Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2019 in Research Integrity and Peer Review
Verified
Journal Article
Open access
PDF file
CBChristopher Baethge
Christopher Baethge
SGSandra Goldbeck-Wood
Sandra Goldbeck-Wood
SMStephan Mertens
Stephan Mertens
Narrative reviews are the commonest type of articles in the medical literature. However, unlike systematic reviews and randomized controlled trials (RCT) articles, for which formal instruments exist to evaluate quality, there is currently no instrument available to assess the quality of narrative reviews. In response to this gap, we developed SANRA, the Scale for the Assessment of Narrative Review Articles. A team of three experienced journal editors modified or deleted items in an earlier SANRA version based on face validity, item-total correlations, and reliability scores from previous tests. We deleted an item which addressed a manuscript’s writing and accessibility due to poor inter-rater reliability. The six items which form the revised scale are rated from 0 (low standard) to 2 (high standard) and cover the following topics: explanation of (1) the importance and (2) the aims of the review, (3) literature search and (4) referencing and presentation of (5) evidence level and (6) relevant endpoint data. For all items, we developed anchor definitions and examples to guide users in filling out the form. The revised scale was tested by the same editors (blinded to each other’s ratings) in a group of 30 consecutive non-systematic review manuscripts submitted to a general medical journal. Raters confirmed that completing the scale is feasible in everyday editorial work. The mean sum score across all 30 manuscripts was 6.0 out of 12 possible points (SD 2.6, range 1–12). Corrected item-total correlations ranged from 0.33 (item 3) to 0.58 (item 6), and Cronbach’s alpha was 0.68 (internal consistency). The intra-class correlation coefficient (average measure) was 0.77 [95% CI 0.57, 0.88] (inter-rater reliability). Raters often disagreed on items 1 and 4. SANRA’s feasibility, inter-rater reliability, homogeneity of items, and internal consistency are sufficient for a scale of six items. Further field testing, particularly of validity, is desirable. We recommend rater training based on the “explanations and instructions” document provided with SANRA. In editorial decision-making, SANRA may complement journal-specific evaluation of manuscripts—pertaining to, e.g., audience, originality or difficulty—and may contribute to improving the standard of non-systematic reviews.

15 September 2021 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
HBHenry Bode
Henry Bode
BIBeatrice Ivens
Beatrice Ivens
TBTom Bschor
Tom Bschor
GSGuido Schwarzer
Guido Schwarzer
JHJonathan Henssler
Jonathan Henssler
CBChristopher Baethge
Christopher Baethge
The symptoms of hypothyroidism and depression partly overlap, but for decades, a more specific link between both disorders has been discussed.1 Neurobiological research has uncovered some mechanisms of thyroid hormones in the brain, providing possible explanations for an interaction with mood.2,3 Also, immunologic processes may provide a link between autoimmune thyroiditis and depression.4,5

16 February 2022 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
JHJonathan Henssler
Jonathan Henssler
DADavid Alexander
David Alexander
GSGuido Schwarzer
Guido Schwarzer
TBTom Bschor
Tom Bschor
CBChristopher Baethge
Christopher Baethge
Guidelines by the National Institute for Health and Care Excellence,1 American Psychological Association,2 and American Psychiatric Association,3 as well as the German National Clinical Practice Guideline4 recommend use of a single, non–monoamine oxidase inhibitor antidepressant as initial treatment in severe depression. Despite a host of antidepressant agents, response rates to initial antidepressant monotherapy hover at 60%, and remissions occur in only up to 40% of patients, even after 12 to 24 weeks of treatment.5

5 June 2024 in The Lancet Psychiatry
Verified
Journal Article
Open access
JHJonathan Henssler
Jonathan Henssler
YSYannick Schmidt
Yannick Schmidt
USUrszula Schmidt
Urszula Schmidt
GSGuido Schwarzer
Guido Schwarzer
TBTom Bschor
Tom Bschor
CBChristopher Baethge
Christopher Baethge
Antidepressant discontinuation symptoms are becoming an increasingly important part of clinical practice, but the incidence of antidepressant discontinuation symptoms has not been quantified. An estimate of antidepressant discontinuation symptoms incidence could inform patients and clinicians in the discontinuation of treatment, and provide useful information to researchers in antidepressant treatments. We aimed to assess the incidence of antidepressant discontinuation symptoms in patients discontinuing both antidepressants and placebo in the published literature. We systematically searched Medline, EMBASE, and CENTRAL from database inception until Oct 13, 2022 for randomised controlled trials (RCTs), other controlled trials, and observational studies assessing the incidence of antidepressant discontinuation symptoms. To be included, studies must have investigated cessation or tapering of an established antidepressant drug (excluding antipsychotics, lithium, or thyroxine) or placebo in participants with any mental, behavioural, or neurodevelopmental disorder. We excluded studies in neonates, and those using antidepressants for physical conditions such as pain syndromes due to organic disease. After study selection, summary data extraction, and risk of bias evaluation, data were pooled in random-effects meta-analyses. The main outcome was the incidence of antidepressant discontinuation symptoms after discontinuation of antidepressants or placebo. We also analysed the incidence of severe discontinuation symptoms. Sensitivity and meta-regression analyses tested a selection of methodological variables. From 6095 articles screened, 79 studies (44 RCTs and 35 observational studies) covering 21 002 patients were selected (72% female, 28% male, mean age 45 years [range 19·6-64·5]). Data on ethnicity were not consistently reported. 16 532 patients discontinued from an antidepressant, and 4470 patients discontinued from placebo. Incidence of at least one antidepressant discontinuation symptom was 0·31 (95% CI 0·27-0·35) in 62 study groups after discontinuation of antidepressants, and 0·17 (0·14-0·21) in 22 study groups after discontinuation of placebo. Between antidepressant and placebo groups of included RCTs, the summary difference in incidence was 0·08 [0·04-0·12]. The incidence of severe antidepressant discontinuation symptoms after discontinuation of an antidepressant was 0·028 (0·014-0·057) compared with 0·006 (0·002-0·013) after discontinuation of placebo. Desvenlafaxine, venlafaxine, imipramine, and escitalopram were associated with higher frequencies of discontinuation symptoms, and imipramine, paroxetine, and either desvenlafaxine or venlafaxine were associated with a higher severity of symptoms. Heterogeneity of results was substantial. Considering non-specific effects, as evidenced in placebo groups, the incidence of antidepressant discontinuation symptoms is approximately 15%, affecting one in six to seven patients who discontinue their medication. Subgroup analyses and heterogeneity figures point to factors not accounted for by diagnosis, medication, or trial-related characteristics, and might indicate subjective factors on the part of investigators, patients, or both. Residual or re-emerging psychopathology needs to be considered when interpreting the results, but our findings can inform clinicians and patients about the probable extent of antidepressant discontinuation symptoms without causing undue alarm. None.

13 November 2020 in Addiction
Verified
Journal Article
Open access
PDF file
JHJonathan Henssler
Jonathan Henssler
MMMartin Müller
Martin Müller
HCHelena Carreira
Helena Carreira
TBTom Bschor
Tom Bschor
AHAndreas Heinz
Andreas Heinz
CBChristopher Baethge
Christopher Baethge
Background and Aims: The proportion of untreated patients with alcohol use disorder (AUD) exceeds that of any other mental health disorder, and treatment alternatives are needed. A widely discussed strategy is to depart from the abstinence paradigm as part of controlled drinking approaches. This first systematic review with meta‐analysis aims to assess the efficacy of non‐abstinent treatment strategies compared with abstinence‐based strategies.Methods: CENTRAL, PubMed, PsycINFO and Embase databases were searched until February 2019 for controlled (randomized and non‐randomized) clinical trials (RCTs and non‐RCTs) among adult AUD populations, including an intervention group aiming at controlled drinking and a control group aiming for abstinence. Following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and Cochrane Collaboration guidelines, literature search, data collection and risk of bias assessment were carried out independently by two reviewers [International Prospective Register of Systematic Reviews (PROSPERO), registration no. CRD42019128716]. The primary outcome was the proportion of participants consuming alcohol at or below the recommended threshold. Secondary outcomes were social functioning, drinking reductions, abstinence rates and dropouts. Using random‐effects models, RCTs and non‐RCTs were analyzed separately. Sensitivity and subgroup analyses accounted for methodological rigor, inclusion of goal‐specific treatment, length of follow‐up and AUD severity.Results: Twenty‐two studies (including five RCTs) with 4204 patients were selected. There was no statistically significant difference between both treatment paradigms in RCTs [odds ratio (OR) = 1.32, 95% confidence interval (CI) = 0.51–3.39]. Non‐randomized studies of free goal choice favored abstinence‐orientation (OR = 0.60, 95% CI = 0.40–0.90), unless goal‐specific treatment was provided (OR = 0.79, 95% CI = 0.40–1.56), or in studies of low risk of bias (OR = 0.73, 95% CI = 0.49–1.09) or with long follow‐up (OR = 1.49, 95% CI = 0.78–2.85). Effect sizes were not clearly dependent upon AUD severity. Abstinence‐ and controlled drinking interventions did not clearly differ in their effect on social functioning and drinking reductions.Conclusions: Available evidence does not support abstinence as the only approach in the treatment of alcohol use disorder. Controlled drinking, particularly if supported by specific psychotherapy, appears to be a viable option where an abstinence‐oriented approach is not applicable.

21 March 2013 in Psychotherapy and Psychosomatics
Verified
Journal Article
Closed access
PDF file
CBChristopher Baethge
Christopher Baethge
OAOliver P. Assall
Oliver P. Assall
RBRoss J. Baldessarini
Ross J. Baldessarini
Background: Blinding is an integral part of many randomized controlled trials (RCTs). However, both blinding and blinding assessment seem to be rarely documented in trial reports. Method: Systematic review of articles on RCTs in schizophrenia and affective disorders research during 2000-2010. Results: Among 2,467 publications, 61 (2.5%; 95% confidence interval: 1.9-3.1%) reported assessing participant, rater, or clinician blinding: 5/672 reports on schizophrenia (0.7%; 0.3-1.6%) and 33/1,079 (3.1%; 2.1-4.2%) on affective disorders, without significant trends across the decade. Rarely was blinding assessed at the beginning, in most studies assessment was at the end. Proportion of patients' and raters' correct guesses of study arm averaged 54.4 and 62.0% per study, with slightly more correct guesses in treatment arms than in placebo arms. Three fourths of responders correctly guessed that they received the active agent. Blinding assessment was more frequently reported in papers on psychotherapy and brain stimulation than on drug trials (5.1%, 1.7-11.9%, vs. 8.3%, 4.3-14.4%, vs. 2.1%, 1.5-2.8%). Lack of assessment of blinding was associated with: (a) positive findings, (b) full industrial sponsorship, and (c) diagnosis of schizophrenia. There was a moderate association of treatment success and blinding status of both trial participants (r = 0.51, p = 0.002) and raters (r = 0.55, p = 0.067). Many RCT reports did not meet CONSORT standards regarding documentation of persons blinded (60%) or of efforts to match interventions (50%). Conclusions: Recent treatment trials in major psychiatric disorders rarely reported on or evaluated blinding. We recommend routine documentation of blinding strategies in reports.